Vor Biopharma Inc

NASDAQ VOR

Data sourced from

and

Daily

Download Data

Vor Biopharma Inc Price to Earnings Ratio (P/E) on June 03, 2024: -3.26

Vor Biopharma Inc Price to Earnings Ratio (P/E) is -3.26 on June 03, 2024, a 3.52% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Vor Biopharma Inc 52-week high Price to Earnings Ratio (P/E) is -0.00 on March 14, 2024, which is 99.93% above the current Price to Earnings Ratio (P/E).
Vor Biopharma Inc 52-week low Price to Earnings Ratio (P/E) is -1,661.46 on August 08, 2023, which is -50,927.75% below the current Price to Earnings Ratio (P/E).
Vor Biopharma Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -21.86.

NASDAQ: VOR

Vor Biopharma Inc

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
IPO Date	Feb. 5, 2021
Location	United States
Headquarters	100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees	168
Sector	Healthcare
Industry	Biotechnology

Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key trends